Curetis had expenses of EUR 12m in the first half of 2019 and revenues of EUR 1m. The company was not profitable and merged with OpGen. This is not a pick for the Defensive Investor.
In Septemver 2018 the stock price was EUR 3,70 and book value was 92 cents. Now the stock price is 61 cents. I don't know the book value after the deal with OpGen. Could be an opportunity, but for me it is on the "too difficult pile" and outside my circle of competence for now.